Shalom Auerbach sold $82k of OSTX
owner at OS Therapies Inc. 60,012 shares at an average of $1.36, traded Apr 9, 2025, filed Apr 11, 2025.
Score components
- +12Role10% owner
- +9Trade size$82k at market
- 0Share of holdings soldSold 2.1% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +56.0%, 3m +36.0%, 6m +59.2%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001641172-25-003926, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 9, 2025 | SOpen-market sale Common Stock, par value $0.001 per shareindirect: See Footnote | -50,012 | $1.35 | $68k | 2,756,199 | Apr 11, 2025 |
| Apr 10, 2025 | SOpen-market sale Common Stock, par value $0.001 per shareindirect: See Footnote | -10,000 | $1.39 | $14k | 2,746,199 | Apr 11, 2025 |
Related signals
Other insiders at OS Therapies Inc and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | OSTXsell OS Therapies Inc | Shalom Auerbach owner | $164k 82,000 shares | -3% | |
| 26Weak | OSTXsell OS Therapies Inc | Shalom Auerbach owner | $284k 100,000 shares | -4% | |
| 22Weak | OSTXsell OS Therapies Inc | Shalom Auerbach owner | $113k 16,720 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.